Back to top
more

BeiGene (BGNE)

(Real Time Quote from BATS)

$142.21 USD

142.21
90,416

+3.22 (2.32%)

Updated Apr 24, 2024 12:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BGNE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for BeiGene, Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 3,186 4,535 6,618 4,651 983
Receivables 358 173 483 60 71
Notes Receivable 0 0 0 0 0
Inventories 416 282 243 89 29
Other Current Assets 243 217 270 160 90
Total Current Assets 4,203 5,207 7,614 4,961 1,173
Net Property & Equipment 1,324 846 588 358 242
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 110 66 38
Intangibles 57 41 47 5 6
Deposits & Other Assets 125 176 170 121 71
Total Assets 5,805 6,379 8,646 5,601 1,612
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 329 428 335 0
Accounts Payable 315 295 262 232 122
Current Portion Long-Term Debt 688 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 694 467 558 346 164
Income Taxes Payable 23 25 21 20 13
Other Current Liabilities 68 328 308 128 0
Total Current Liabilities 1,810 1,469 1,600 1,075 310
Mortgages 0 0 0 0 0
Deferred Taxes/Income 17 58 234 11 11
Convertible Debt 0 0 0 0 0
Long-Term Debt 198 209 202 184 241
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 221 226 324 432 47
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,268 1,996 2,403 1,732 634
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 11,599 11,541 11,191 7,415 2,926
Retained Earnings -7,962 -7,080 -4,966 -3,553 -1,956
Other Equity -99 -77 18 7 8
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 3,537 4,383 6,243 3,869 978
Total Liabilities & Shareholder's Equity 5,805 6,379 8,646 5,601 1,612
Total Common Equity 3,537 4,383 6,243 3,869 978
Shares Outstanding 95.30 103.90 102.40 91.10 61.60
Book Value Per Share 37.12 42.19 60.97 42.47 15.88

Fiscal Year End for BeiGene, Ltd falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 3,186 3,186 3,526 3,833
Receivables NA 358 309 299 310
Notes Receivable NA 0 0 0 0
Inventories NA 416 317 321 297
Other Current Assets NA 243 242 255 265
Total Current Assets NA 4,203 4,054 4,401 4,704
Net Property & Equipment NA 1,324 1,178 1,032 925
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 57 54 47 40
Deposits & Other Assets NA 125 141 149 178
Total Assets NA 5,805 5,525 5,729 5,957
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 329 421 282
Accounts Payable NA 315 342 267 241
Current Portion Long-Term Debt NA 688 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 694 506 455 418
Income Taxes Payable NA 23 20 17 34
Other Current Liabilities NA 68 64 222 255
Total Current Liabilities NA 1,810 1,283 1,405 1,255
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 17 17 40 53
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 198 202 207 206
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 234 252 253
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,268 1,762 1,930 1,799
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 11,599 11,503 11,752 11,645
Retained Earnings NA -7,962 -7,595 -7,810 -7,429
Other Equity NA -99 -145 -144 -59
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 3,537 3,763 3,799 4,157
Total Liabilities & Shareholder's Equity NA 5,805 5,525 5,729 5,957
Total Common Equity 0 3,537 3,763 3,799 4,157
Shares Outstanding 95.50 95.30 97.00 96.60 104.80
Book Value Per Share 0.00 37.12 38.80 39.32 39.67